WallStSmart

Blackbaud Inc (BLKB)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Blackbaud Inc generates 336% more annual revenue ($1.13B vs $258.90M). BLKB leads profitability with a 10.2% profit margin vs -15.5%. BLKB earns a higher WallStSmart Score of 64/100 (C+).

BLKB

Buy

64

out of 100

Grade: C+

Growth: 5.3Profit: 7.0Value: 9.3Quality: 4.3
Piotroski: 6/9Altman Z: 0.57

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BLKBUndervalued (+48.0%)

Margin of Safety

+48.0%

Fair Value

$96.95

Current Price

$37.17

$59.78 discount

UndervaluedFair: $96.95Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLKB4 strengths · Avg: 9.5/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
108.5%10/10

Every $100 of equity generates 109 in profit

EPS GrowthGrowth
180.0%10/10

Earnings expanding 180.0% YoY

P/E RatioValuation
15.8x8/10

Attractively priced relative to earnings

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

BLKB4 concerns · Avg: 2.3/10
Market CapQuality
$1.73B3/10

Smaller company, higher risk/reward

Price/BookValuation
20.1x2/10

Trading at 20.1x book value

Revenue GrowthGrowth
-2.3%2/10

Revenue declined 2.3%

Altman Z-ScoreHealth
0.572/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BLKB

The strongest argument for BLKB centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : BLKB

The primary concerns for BLKB are Market Cap, Price/Book, Revenue Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BLKB profiles as a declining stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BLKB scores higher overall (64/100 vs 41/100). ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Blackbaud Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Blackbaud, Inc. provides cloud software solutions to nonprofits, foundations, businesses, educational institutions, healthcare organizations, and other social concern entities in the United States and internationally. The company is headquartered in Charleston, South Carolina.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?